The Hartford Announces Expanded Roles For CIO Deepa Soni And John Kinney, Head Of Claims & Operations

The Hartford Announces Expanded Roles For CIO Deepa Soni And John Kinney, Head Of Claims & Operations

Bill Bloom, head of claims, operations, technology, data and analytics, to retire later this year

HARTFORD, Conn.–(BUSINESS WIRE)–The Hartford expanded roles for two executives, Deepa Soni and John Kinney, who will report directly to The Hartford’s Chairman and CEO Christopher Swift effective Aug. 2. Soni, the company’s chief information officer, now oversees Technology, Data, Analytics & Information Security. Kinney’s responsibilities were recently broadened to include Operations in addition to his role overseeing Claims. Soni and Kinney are succeeding Bill Bloom, who will retire later this year as head of Claims, Operations, Technology, Data and Analytics.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210701005343/en/

Deepa Soni (Photo: Business Wire)

Deepa Soni (Photo: Business Wire)

“Over the past several years, The Hartford has pursued an aggressive technology agenda, expanding digital capabilities, simplifying processes and platforms, and applying data and analytics to enhance products and services,” Swift said. “Deepa has elevated our technology capabilities through an emphasis on agile approaches, cloud-based digital platforms, automation and advanced data and analytics. John is a proven leader who can deliver a truly differentiating end-to-end customer experience with our united Claims and Operations organization.”

Soni joined The Hartford in September 2019 after growing her career in the banking sector. As the chief information officer, she has been responsible for the enterprise’s information technology applications, infrastructure and architecture. Kinney joined The Hartford in 2003 and has overseen the company’s claims organization since 2013. Prior to that, he led the company’s property and casualty field claims organization. Kinney is the company’s executive sponsor of the Black Insurance Professionals Network.

Mary Nasenbenny succeeds Kinney as chief claims officer and is now a member of The Hartford’s Executive Leadership Team. Since joining the company in 1999, Nasenbenny has held leadership positions across Claims, most recently leading the company’s Workers’ Compensation/Group Benefits Claims and Health Services Teams.

Since rejoining The Hartford in 2014, Bloom has led the transformation of the company’s Operations, Technology, Data and Analytics capabilities. Bloom was a strong advocate for talent development and served as the executive sponsor of the Professional Women’s Network employee resource group.

Swift added, “Bill oversaw the implementation of a robust investment agenda that has dramatically enhanced our ability to win business, and efficiently and profitably serve our customers. He has provided thoughtful and strategic counsel, and we are grateful for his leadership and value the many contributions he has made to the company.”

About The Hartford

The Hartford is a leader in property and casualty insurance, group benefits and mutual funds. With more than 200 years of expertise, The Hartford is widely recognized for its service excellence, sustainability practices, trust and integrity. More information on the company and its financial performance is available at https://www.thehartford.com. Follow us on Twitter at @TheHartford_PR.

The Hartford Financial Services Group, Inc., (NYSE: HIG) operates through its subsidiaries under the brand name, The Hartford, and is headquartered in Hartford, Connecticut. For additional details, please read The Hartford’s legal notice.

HIG-C

Some of the statements in this release may be considered forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. We caution investors that these forward-looking statements are not guarantees of future performance, and actual results may differ materially. Investors should consider the important risks and uncertainties that may cause actual results to differ. These important risks and uncertainties include those discussed in our 2020 Annual Report on Form 10-K, subsequent Quarterly Reports on Forms 10-Q, and the other filings we make with the Securities and Exchange Commission. We assume no obligation to update this release, which speaks as of the date issued.

From time to time, The Hartford may use its website and/or social media outlets, such as Twitter and Facebook, to disseminate material company information. Financial and other important information regarding The Hartford is routinely accessible through and posted on our website at https://ir.thehartford.com, Twitter account at www.twitter.com/TheHartford_PR and Facebook at https://facebook.com/thehartford. In addition, you may automatically receive email alerts and other information about The Hartford when you enroll your email address by visiting the “Email Alerts” section at https://ir.thehartford.com.

Media Contact:

Matthew Sturdevant

860-547-8664

[email protected]

Investor Contact:

Susan Spivak Bernstein

860-547-6233

[email protected]

KEYWORDS: United States North America Connecticut

INDUSTRY KEYWORDS: Insurance Professional Services

MEDIA:

Logo
Logo
Photo
Photo
Deepa Soni (Photo: Business Wire)
Photo
Photo
John Kinney (Photo: Business Wire)

AdvanSix to Release Second Quarter Financial Results and Hold Investor Conference Call on July 30

AdvanSix to Release Second Quarter Financial Results and Hold Investor Conference Call on July 30

PARSIPPANY, N.J.–(BUSINESS WIRE)–
AdvanSix (NYSE: ASIX) will issue its second quarter 2021 financial results before the opening of the New York Stock Exchange on Friday, July 30. The company will also hold a conference call with investors at 9:00 a.m. ET that day.

Conference Call Details

To participate on the conference call, dial (833) 756-0862 (domestic) or (412) 317-5752 (international) approximately 10 minutes before the 9:00 a.m. ET start, and tell the operator that you are dialing in for AdvanSix’s second quarter 2021 earnings call. A replay of the conference call will be available from 12 noon ET on July 30 until 12 noon ET on August 6. You can listen to the replay by dialing (877) 344-7529 (domestic) or (412) 317-0088 (international). The access code is 10153579.

Presentation Materials / Webcast Details

A real-time audio webcast of the presentation can be accessed at http://investors.advansix.com. Related materials will be posted prior to the presentation at that site, and a replay of the webcast will be available on the AdvanSix investor website for 90 days following the presentation.

About AdvanSix

AdvanSix plays a critical role in global supply chains, innovating and delivering essential products for our customers in a wide variety of end markets and applications that touch people’s lives, such as building and construction, fertilizers, plastics, solvents, packaging, paints, coatings, adhesives and electronics. Our reliable and sustainable supply of quality products emerges from the vertically integrated value chain of our three U.S.-based manufacturing facilities. AdvanSix strives to deliver best-in-class customer experiences and differentiated products in the industries of nylon solutions, chemical intermediates, and plant nutrients, guided by our core values of Safety, Integrity, Accountability and Respect. More information on AdvanSix can be found at http://www.advansix.com.

Media

Debra Lewis

(973) 526-1767

[email protected]

Investors

Adam Kressel

(973) 526-1700

[email protected]

KEYWORDS: United States North America New Jersey

INDUSTRY KEYWORDS: Other Manufacturing Textiles Packaging Other Energy Chemicals/Plastics Manufacturing Energy Agriculture Natural Resources

MEDIA:

Logo
Logo

IGT Environmental, Social and Governance Improved Performance, Diversity and Inclusion Initiatives and Responsible Gaming Approach Anchor its 14th Annual Sustainability Report

Company exhibits unrivaled gaming industry leadership in latest report

PR Newswire

LONDON, July 1, 2021 /PRNewswire/ — International Game Technology PLC (“IGT”) (NYSE:IGT) has announced the release of its 2020 Sustainability Report, which outlines the Company’s improved environmental, social and governance (ESG) performance year-over-year. IGT’s 14th annual Sustainability Report demonstrates the Company’s drive to create value, increase its socially responsible corporate citizenship and enhance reporting on its activities.

“IGT’s 2020 Sustainability Report underscores and highlights our unwavering commitment to sustainability even while our business adjusted to new ways of working during the COVID-19 pandemic,” said Marco Sala, IGT CEO. “Several of the most reputable ESG analysts and rating agencies recognized IGT for improving the quality of the information that we disclose and the sustainable activities and solutions that we implemented across the Company. We firmly believe that IGT’s continued dedication to the well-being and development of our employees and high standards of corporate citizenship creates value for our stakeholders throughout the world.”

IGT focuses its corporate social responsibility activities on four key pillars: Valuing and Protecting Our People, Advancing Responsibility, Supporting Our Communities and Fostering Sustainable Operations. The 2020 Sustainability Report illustrates IGT’s achievements in generating value for a range of stakeholder groups including employees, customers, communities and suppliers.

Highlights of the report include:

  • Valuing and Protecting Our People: IGT is dedicated to maintaining a fair, inclusive culture where all employees feel valued, respected, engaged and empowered to contribute to the business. IGT enriches employee development through career pathing and mentoring. The Company’s Office of Diversity & Inclusion guides strategic diversity and inclusion initiatives and embeds these topics in our business processes.
    • IGT prioritized the health and safety of employees, customers and partners in 2020. New ways of working were implemented at the outset of the COVID-19 pandemic to ensure all employees were provided with a safe working environment, whether remotely or onsite, to minimize the potential spread of the virus.
    • IGT was selected for the 2020 Bloomberg Gender-Equality Index for the Company’s commitment to progressing diversity and inclusion in the workplace. The Bloomberg Gender-Equality Index distinguishes companies committed to advancing women’s equality and transparently reporting gender data.
  • Advancing Responsibility: IGT is committed to player protection and product integrity. Through its comprehensive responsible gaming program, IGT contributes features and capabilities to promote safer gambling and prevent underage play. A solid infrastructure of policies, guidelines and best practices support IGT’s solutions to uphold industry standards and demonstrate reliability throughout its portfolio.
    • In 2020, IGT’s responsible gaming certification from the Global Gambling Guidance Group (G4) was attained for another three years. IGT remains the first gaming vendor in the world to achieve this accreditation for its land-based casino and digital operations.
    • IGT also holds the certification for compliance with the World Lottery Association’s Associate Member Corporate Social Responsibility Standards and Certification Framework for its lottery operations.
  • Supporting Our Communities: IGT supports communities where it operates and where its employees live through corporate programs that align with the United Nations’ sustainable development goals (SDGs). IGT’s Community Ambassador program focuses on community engagement at the local level while aligning with global giving efforts. Employee-driven giving programs complement the corporate programs by supporting the local causes that are important to individual employees.
    • IGT modified its Charitable Giving Guidelines in 2020 to focus on aiding community partners whose operations faced significant challenges due to COVID-19. IGT prioritized funding requests that aligned with the SDGs that supported basic needs. The Company held its first virtual volunteering week with an array of events that brought awareness of how community-based organizations became resilient in hard times and how employees could still support the various causes.
  • Fostering Sustainable Operations: Interacting with customers is an essential element of IGT’s sustainability practices. Sound business relations with suppliers and customers are essential to maintain quality goods and services. IGT ensures its suppliers meet high economic, ethical and environmental standards as outlined in IGT’s Supplier Code of Conduct. In addition, IGT strives to continually improve its environmental management systems and processes to reduce its environmental impact.
    • IGT’s printing facility in Lakeland, Fla. implemented a waste reclamation program that removed approximately 7,175,050 pounds of waste from landfills in 2020, of which approximately 1,073,380 pounds was used to make alternative fuel. For this program, IGT’s facility was recognized as the winner of the Sustainability Program in the 2021 FTA Sustainability Excellence Awards.

IGT continues to look ahead, connecting players around the world with best-in-class solutions that respect people and the environment, while delivering excellence to keep gaming fun and safe for all. The 2020 Sustainability Report is available online at www.IGT.com.

About IGT
IGT (NYSE:IGT) is the global leader in gaming. We deliver entertaining and responsible gaming experiences for players across all channels and regulated segments, from Gaming Machines and Lotteries to Sports Betting and Digital. Leveraging a wealth of compelling content, substantial investment in innovation, player insights, operational expertise, and leading-edge technology, our solutions deliver unrivaled gaming experiences that engage players and drive growth. We have a well-established local presence and relationships with governments and regulators in more than 100 countries around the world, and create value by adhering to the highest standards of service, integrity, and responsibility. IGT has approximately 11,000 employees. For more information, please visit www.igt.com.

Cautionary Statement Regarding Forward-Looking Statements

This news release may contain forward-looking statements (including within the meaning of the Private Securities Litigation Reform Act of 1995) concerning International Game Technology PLC and its consolidated subsidiaries (the “Company“) and other matters. These statements may discuss goals, intentions, and expectations as to future plans, trends, events, dividends, results of operations, or financial condition, or otherwise, based on current beliefs of the management of the Company as well as assumptions made by, and information currently available to, such management. Forward-looking statements may be accompanied by words such as “aim,” “anticipate,” “believe,” “plan,” “could,” “would,” “should,” “shall”, “continue,” “estimate,” “expect,” “forecast,” “future,” “guidance,” “intend,” “may,” “will,” “possible,” “potential,” “predict,” “project” or the negative or other variations of them. These forward-looking statements speak only as of the date on which such statements are made and are subject to various risks and uncertainties, many of which are outside the Company’s control. Should one or more of these risks or uncertainties materialize, or should any of the underlying assumptions prove incorrect, actual results may differ materially from those predicted in the forward-looking statements and from past results, performance, or achievements. Therefore, you should not place undue reliance on such statements. Factors that could cause actual results to differ materially from those in the forward-looking statements include (but are not limited to) the factors and risks described in the Company’s annual report on Form 20-F for the financial year ended December 31, 2020 and other documents filed from time to time with the SEC, which are available on the SEC’s website at www.sec.gov and on the investor relations section of the Company’s website at www.IGT.com. Except as required under applicable law, the Company does not assume any obligation to update these forward-looking statements. You should carefully consider these factors and other risks and uncertainties that affect the Company’s business. All forward-looking statements contained in this news release are qualified in their entirety by this cautionary statement. All subsequent written or oral forward-looking statements attributable to International Game Technology PLC, or persons acting on its behalf, are expressly qualified in their entirety by this cautionary statement.

Contact:

Phil O’Shaughnessy, Global Communications, toll free in U.S./Canada +1 (844) IGT-7452; outside U.S./Canada +1 (401) 392-7452
Francesco Luti, +39 3485475493; for Italian media inquiries
James Hurley, Investor Relations, +1 (401) 392-7190

© 2021 IGT

The trademarks and/or service marks used herein are either trademarks or registered trademarks of IGT, its affiliates or its licensors.

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/igt-environmental-social-and-governance-improved-performance-diversity-and-inclusion-initiatives-and-responsible-gaming-approach-anchor-its-14th-annual-sustainability-report-301323670.html

SOURCE International Game Technology PLC

CNX Establishes Foundation To Govern $30M Commitment To Local Community

Six-Year Charitable Pledge Under New Foundation Drives Long-Term, Sustainable Returns in Tri-State Region

PR Newswire

PITTSBURGH, July 1, 2021 /PRNewswire/ — CNX Resources Corp. (NYSE: CNX) today announced that it has established the CNX Foundation, a 501(c)(3) nonprofit organization funded by CNX Resources, to manage its previously announced $30M community commitment to drive long-term, sustainable return on investment and broaden the path to the middle class throughout the Appalachian region.

“CNX’s approach to community investment is directly tied to our unique Environmental, Social, and Governance (ESG) philosophy,” said Nick DeIuliis, President and CEO of CNX Resources. “Tangible, impactful, and local is our brand of ESG, and the Foundation will partner with organizations who match those criteria and are aligned with our objective to make a meaningful impact in our local, underserved communities. We believe our approach to ESG will define effective leadership in this arena for our industry and the regional business community at large.”

Managed by internal leaders responsible for execution of the Company’s ESG efforts, advised by external community partners, and governed by the CNX board of directors’ Environmental, Safety, and Corporate Responsibility Committee, the CNX Foundation will place particular emphasis on social and environmental impact. Through the end of 2027, CNX intends to invest approximately $17.5M in social efforts and $12.5M in environmental efforts and seeks to partner with local communities to take on substantial projects and help solve complex socio-economic issues facing the region. Key areas of focus include food insecurity, children’s health and wellness, recidivism and re-entry, the opioid epidemic and its societal impact, career awareness and technical/vocational training, and water quality and safety.

External advisory members of the CNX Foundation Board of Directors include:

  • John Bettis, Bettis Brothers Sand & Gravel and The Bus Stops Here Foundation
  • Jeff Nobers, Executive Director, Builders Guild of Western Pennsylvania
  • Brian Jackson, Superintendent, West Greene School District

Brian Aiello, Vice President of External Relations and Human Resources at CNX, will serve as Foundation Chair and Audric Dodds, Director of Community Relations and Strategic Partnerships at CNX, will serve as Executive Director.

Since first announcing the philanthropic commitment in the spring of 2021, CNX has already committed $1.7M to several signature projects, including:

  • $1M for broadband access in rural Greene County, PA;
  • $400,000 for career training for students/graduates of the recently announced regional mentorship academy;
  • $200,000 for the Jerome Bettis Cyber Bus Project to support technology needs in disadvantaged school districts; and
  • $100,000 for House of Life of Pittsburgh for returning citizen re-entry.

The CNX Foundation welcomes organizations within the tri-state region who seek to apply for a grant to complete an application here. Applications will be reviewed on a quarterly basis. Additional CNX Foundation updates can be found on the Foundation website here.

These investments represent a re-allocation of previously planned expenditures and are expected to generate long-term, sustainable economic returns for the region and the Company by removing barriers to socio-economic diversity and inclusion across the natural gas industry and beyond. The commitment will be effectuated while still allowing the Company to deliver on its previously announced, multi-year free cash flow generation plan.         

To learn more about CNX’s unique Environmental, Social, and Governance (ESG) approach, accomplishments, and goals, please visit: https://responsibility.cnx.com/esg-overview.html.

About CNX Resources Corporation:
CNX Resources Corporation (NYSE: CNX) is the premier independent natural gas development, production, and midstream company, with operations centered in the major shale formations of the Appalachian basin. Our vertically integrated model includes transmission, storage, gathering systems, and water infrastructure that support energy development from wellhead to end user. With the benefit of a more than 150-year legacy and a substantial asset base amassed over many generations, the company deploys a strategy focused on responsibly developing its resources to create long term per share value for its shareholders, employees, and the communities where it operates. As of December 31, 2020, CNX had 9.55 trillion cubic feet equivalent of proved natural gas reserves. The company is a member of the Standard & Poor’s Midcap 400 Index. Additional information may be found at www.cnx.com.


# # #





 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/cnx-establishes-foundation-to-govern-30m-commitment-to-local-community-301323625.html

SOURCE CNX Resources Corporation

Ault Global Holdings Announces That Alzamend Neuro Has Submitted an IND Application for AL001 for Dementia Related to Alzheimer’s Disease

Ault Global Holdings Announces That Alzamend Neuro Has Submitted an IND Application for AL001 for Dementia Related to Alzheimer’s Disease

LAS VEGAS–(BUSINESS WIRE)–Ault Global Holdings, Inc. (NYSE American: DPW) a diversified holding company (the “Company”), announced today that Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a preclinical stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, submitted an investigational new drug (“IND”) application to the FDA for the initiation of a Phase 1 clinical study of AL001 on June 30, 2021. The Phase 1, first-in-human study, is designed for the purpose of determining potential clinically safe and appropriate AL001 dosing in future studies. AL001 is a lithium-based ionic cocrystal oral therapy for patients with dementia related to mild, moderate, and severe cognitive impairment associated with Alzheimer’s disease.

Following completion of this initial study, Alzamend intends to initiate a Phase 1/2a clinical trial designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of AL001 in Alzheimer’s disease patients. Presuming favorable data, a subsequent Phase 2b program is planned to target appropriate doses for the pivotal Phase 3 safety/efficacy clinical program required for regulatory approval.

“This IND submission represents a key milestone for Alzamend as we continue to advance our proprietary pipeline. We believe AL001 could potentially provide clinicians with a major improvement over current lithium-based treatments and may constitute a means of treating Alzheimer’s disease and other neurodegenerative diseases and psychiatric disorders. We look forward to providing more details on the timeline and market opportunity following FDA clearance of the IND, if obtained,” commented Stephan Jackman, Chief Executive Officer of Alzamend.

Based on preclinical data, AL001 treatment prevents cognitive deficits, depression, and irritability in APPSWE/PS1dE9 mice, and has shown an improvement of associative learning and memory and irritability compared with lithium carbonate treatments, supporting the potential of this lithium formulation for the treatment of Alzheimer’s disease and psychiatric disorders. Lithium has been marketed for more than 35 years and human toxicology regarding lithium use has been well characterized, potentially allowing Alzamend to rely upon this existing data, potentially reducing the regulatory burden for safety data.

Alzamend’s mission is to help the Alzheimer’s disease community by supporting the full product development life cycle of treatment and cures for dementia and Alzheimer’s disease driven by the belief that strong support of research is the foundation for true innovation. Dementia is not a normal part of aging, and there are numerous symptoms that can indicate cognitive and neurological impairments. Alzheimer’s disease is the most common form of dementia. This disease robs people of their loved ones, as memories are erased and personalities are diminished. Alzamend’s vision statement nicely sums up their mission: “Together We Can ‘Make Alzheimer’s Just a Memory!’™”.

The economic impact of Alzheimer’s disease can be as devastating as the emotional stress. Over 47 million people in the world currently live with Alzheimer’s disease or dementia, with over 6.2 million in the U.S. (two-thirds are women). The lifetime cost of care for an Alzheimer’s disease patient is estimated at $374,000 in the U.S. According to the Alzheimer’s Association, it is estimated that Alzheimer’s and dementia deaths increased more than 16% in 2021 due to COVID-19. In 2021, Alzheimer’s and dementia will cost the U.S. an estimated $355 billion with the costs expected to rise into the trillions in the next 25 years. In, addition, Medicare and Medicaid is expected to pay approximately $239 billion, or 67% of the treatment and long-term care costs associated with Alzheimer’s disease and dementia, with another $79 billion of out-of-pocket costs. According to the Alzheimer’s Association, eleven million Americans provide an estimated 15.3 billion hours of unpaid care per year, valued at $257 billion, for these patients with two-thirds of these being women, and one-third being daughters.

Milton “Todd” Ault, III, the Company’s Executive Chairman, stated, “The Company is pleased that Alzamend has achieved this milestone to further its commitment to develop treatments and cures for Alzheimer’s, other neurodegenerative diseases and psychiatric disorders.”

The Company has certain beneficial ownership and rights to further invest in Alzamend as follows:

  • The Company beneficially owns approximately 5.3 million shares of Alzamend common stock held by its wholly owned subsidiary, Digital Power Lending, LLC (“DPL”).
  • The Company has the right to acquire 1.35 million shares of Alzamend common stock upon the exercise of warrants beneficially owned by DPL.
  • In March 2021, Alzamend entered into a securities purchase agreement with DPL pursuant to which Alzamend agreed to sell an aggregate of 6.7 million shares of its common stock for an aggregate of $10 million, or $1.50 per share, which sales will be made in tranches. Alzamend further agreed to issue to DPL warrants to purchase such number of shares of its common stock equal to 50% of the shares of common stock purchased under the securities purchase agreement at an exercise price of $3.00 per share. On March 9, 2021, the Company purchased 2.7 million shares of Alzamend common stock (included in the 5.3 million shares of Alzamend common stock held by DPL described above) upon closing of the first tranche of $4 million. Under the terms of the securities purchase agreement, DPL may purchase an additional 4.0 million shares.
  • Finally, Alzamend agreed that for a period of 18 months following the date of the payment of the final tranche of $4 million, DPL will have the right to invest an additional $10 million on the same terms, except that no specific milestones have been determined with respect to the additional $10 million.

Should the Company exercise all warrants and options to invest, it would own approximately 22.6 million shares with an average cost of $2.27 per share of common stock, representing 22% of Alzamend’s issued and outstanding common stock.

For more information on Ault Global Holdings and its subsidiaries, the Company recommends that stockholders, investors and any other interested parties read the Company’s public filings with the SEC, available at www.sec.gov, and press releases available under the Investor Relations section at www.AultGlobal.com.

About Ault Global Holdings, Inc.

Ault Global Holdings, Inc. is a diversified holding company pursuing growth by acquiring undervalued businesses and disruptive technologies with a global impact. Through its wholly and majority-owned subsidiaries and strategic investments, the Company provides mission-critical products that support a diverse range of industries, including defense/aerospace, industrial, automotive, telecommunications, medical/biopharma, and textiles. In addition, the Company extends credit to select entrepreneurial businesses through a licensed lending subsidiary. Ault Global Holdings’ headquarters are located at 11411 Southern Highlands Parkway, Suite 240, Las Vegas, NV 89141; www.AultGlobal.com.

About Alzamend Neuro

Alzamend Neuro, Inc. (“Alzamend”) (www.Alzamend.com), is a Delaware corporation with its corporate headquarters in Tampa, Florida. The mission of Alzamend is to help the Alzheimer’s community by supporting the full product development life cycle of treatment and cures of neurodegenerative diseases and psychiatric disorders, including Alzheimer’s disease. With Alzamend’s two current and future product candidates, Alzamend aims to bring treatments or cures to market at a reasonable cost as quickly as possible. Alzamend’s current pipeline consists of two novel therapeutic drug candidates, AL001 – a patented ionic cocrystal technology delivering a therapeutic combination of lithium, proline, and salicylate, and AL002 – a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat Alzheimer’s disease. Both of Alzamend’s product candidates are licensed from the pursuant to royalty-bearing exclusive worldwide licenses from the University of South Florida. www.Alzamend.com

Forward-Looking Statements

This press release contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “believes,” “plans,” “anticipates,” “projects,” “estimates,” “expects,” “intends,” “strategy,” “future,” “opportunity,” “may,” “will,” “should,” “could,” “potential,” or similar expressions. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties. Forward-looking statements speak only as of the date they are made, and the Company undertakes no obligation to update any of them publicly in light of new information or future events. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors. More information, including potential risk factors, that could affect the Company’s business and financial results are included in the Company’s filings with the U.S. Securities and Exchange Commission, including, but not limited to, the Company’s Forms 10-K, 10-Q and 8-K. All filings are available at www.sec.gov and on the Company’s website at www.AultGlobal.com.

[email protected] or 1-888-753-2235

KEYWORDS: Nevada United States North America

INDUSTRY KEYWORDS: Other Manufacturing Technology FDA Other Technology Clinical Trials Manufacturing Biotechnology General Health Pharmaceutical Health

MEDIA:

Logo
Logo

Lindsay Corporation Reports Fiscal 2021 Third Quarter Results

Lindsay Corporation Reports Fiscal 2021 Third Quarter Results

  • Third quarter consolidated revenues increase 32 percent to $161.9 million with EPS of $1.61
  • Higher agriculture commodity prices drive improved demand for irrigation equipment across all geographies
  • Irrigation revenues increase 39 percent in North America and 62 percent in international markets
  • Infrastructure revenues decrease 21 percent due to coronavirus-related project delays

OMAHA, Neb.–(BUSINESS WIRE)–
Lindsay Corporation (NYSE: LNN), a leading global manufacturer and distributor of irrigation and infrastructure equipment and technology, today announced results for its third quarter of fiscal 2021, which ended on May 31, 2021.

Third Quarter Summary

Revenues for the third quarter of fiscal 2021 were $161.9 million, an increase of $38.8 million, or 32 percent, compared to revenues of $123.1 million in the prior year third quarter. Net earnings for the quarter were $17.8 million, or $1.61 per diluted share, compared with net earnings of $10.1 million, or $0.93 per diluted share, for the prior year third quarter.

“Healthy agricultural market fundamentals and positive grower sentiment continue to drive increased global demand for irrigation equipment,” said Randy Wood, President and Chief Executive Officer. “At the same time, raw material inflation and other supply chain issues continue to create challenges and margin headwinds. Our teams have responded well and effectively managed through these dynamic market conditions in order to support our customers.”

Third Quarter Segment Results

Irrigation segment revenues for the third quarter of fiscal 2021 increased $44.7 million, or 47 percent, to $140.2 million, compared to $95.5 million in the prior year third quarter. North America irrigation revenues increased $24.5 million, or 39 percent, to $87.4 million compared to the prior year third quarter. The increase resulted from a combination of higher irrigation equipment unit sales volume and higher average selling prices. The increase was partially offset by lower engineering services revenue. International irrigation revenues of $52.8 million increased $20.2 million, or 62 percent, compared to the prior year third quarter. The increase resulted from higher unit sales volumes in most international markets, higher prices, and favorable foreign currency translation impact of $2.3 million.

Irrigation segment operating income was $23.9 million, an increase of $8.5 million, or 55 percent, compared to the prior year third quarter. Operating margin was 17.1 percent of sales, compared to 16.1 percent of sales in the prior year third quarter. The increase resulted primarily from the impact of higher irrigation system unit volume and was partially offset by the impact of higher raw material and other costs.

Infrastructure segment revenues for the third quarter of fiscal 2021 decreased $5.8 million, or 21 percent, to $21.8 million, compared to $27.6 million in the prior year third quarter. The decrease resulted from lower Road Zipper System® sales, which were partially offset by higher Road Zipper System lease revenue and increased sales of road safety products. Road construction activity and the timing of certain projects continues to be impacted by coronavirus-related delays.

Infrastructure segment operating income was $3.8 million, a decrease of $4.4 million, or 54 percent, compared to the prior year third quarter. Operating margin was 17.3 percent of sales, compared to 29.5 percent of sales in the prior year third quarter. Current year results reflect lower revenues and a less favorable margin mix of revenues compared to the prior year.

The backlog of unfilled orders at May 31, 2021 was $120.8 million compared with $78.6 million at May 31, 2020. The irrigation backlog is higher compared to the prior year while the infrastructure backlog is lower due to two large orders in the prior year that did not repeat.

Outlook

“Market conditions support continued robust demand for irrigation equipment, and we also expect raw material inflation and supply chain challenges to persist through the balance of our fiscal year,” said Mr. Wood. “We remain optimistic about the outlook for our infrastructure business, particularly as coronavirus restrictions are lifted and road construction activity returns to more normal levels.”

Mr. Wood continued, “Our financial position remains strong, providing support for our innovation growth strategy across our businesses that address global megatrends and provide solutions that improve customer profitability and assist in their sustainability efforts.”

Third Quarter Conference Call

Lindsay’s fiscal 2021 third quarter investor conference call is scheduled for 11:00 a.m. Eastern Time today. Interested investors may participate in the call by dialing (833) 535-2202 in the U.S., or (412) 902-6745 internationally, and requesting the Lindsay Corporation call. Additionally, the conference call will be simulcast live on the Internet and can be accessed via the investor relations section of the Company’s Web site, www.lindsay.com. Replays of the conference call will remain on our Web site through the next quarterly earnings release. The Company will have a slide presentation available to augment management’s formal presentation, which will also be accessible via the Company’s Web site.

About the Company

Lindsay Corporation (NYSE: LNN) is a leading global manufacturer and distributor of irrigation and infrastructure equipment and technology. Established in 1955, the company has been at the forefront of research and development of innovative solutions to meet the food, fuel, fiber and transportation needs of the world’s rapidly growing population. The Lindsay family of irrigation brands includes Zimmatic® center pivot and lateral move agricultural irrigation systems and FieldNET® remote irrigation management and scheduling technology, as well as irrigation consulting and design and industrial IoT solutions. Also a global leader in the transportation industry, Lindsay Transportation Solutions manufactures equipment to improve road safety and keep traffic moving on the world’s roads, bridges and tunnels, through the Barrier Systems®, Road Zipper® and Snoline™ brands. For more information about Lindsay Corporation, visit www.lindsay.com.

Concerning Forward-looking Statements

This release contains forward-looking statements that are subject to risks and uncertainties and which reflect management’s current beliefs and estimates of future economic circumstances, industry conditions, Company performance and financial results. You can find a discussion of many of these risks and uncertainties in the annual, quarterly and current reports that the Company files with the Securities and Exchange Commission. Forward-looking statements include information concerning possible or assumed future results of operations and planned financing of the Company and those statements preceded by, followed by or including the words “anticipate,” “estimate,” “believe,” “intend,” “expect,” “outlook,” “could,” “may,” “should,” “will,” or similar expressions. For these statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The Company undertakes no obligation to update any forward-looking information contained in this press release.

 
 
 
 

LINDSAY CORPORATION AND SUBSIDIARIES

 

CONDENSED CONSOLIDATED STATEMENTS OF EARNINGS

 

(Unaudited)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three months ended

 

 

Nine months ended

 

(in thousands, except per share amounts)

 

 

May 31,

2021

 

 

 

May 31,

2020

 

 

 

May 31,

2021

 

 

 

May 31,

2020

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating revenues

 

$

 

161,936

 

 

$

 

123,106

 

 

$

 

413,998

 

 

$

 

346,287

 

Cost of operating revenues

 

 

 

117,880

 

 

 

 

83,410

 

 

 

 

297,360

 

 

 

 

239,111

 

Gross profit

 

 

 

44,056

 

 

 

 

39,696

 

 

 

 

116,638

 

 

 

 

107,176

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Selling expense

 

 

 

7,570

 

 

 

 

7,417

 

 

 

 

22,680

 

 

 

 

22,101

 

General and administrative expense

 

 

 

12,043

 

 

 

 

13,055

 

 

 

 

39,770

 

 

 

 

38,026

 

Engineering and research expense

 

 

 

3,102

 

 

 

 

3,396

 

 

 

 

9,504

 

 

 

 

10,303

 

Total operating expenses

 

 

 

22,715

 

 

 

 

23,868

 

 

 

 

71,954

 

 

 

 

70,430

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating income

 

 

 

21,341

 

 

 

 

15,828

 

 

 

 

44,684

 

 

 

 

36,746

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other (expense) income:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest expense

 

 

 

(1,178

)

 

 

 

(1,197

)

 

 

 

(3,584

)

 

 

 

(3,574

)

Interest income

 

 

 

227

 

 

 

 

408

 

 

 

 

798

 

 

 

 

1,412

 

Other expense, net

 

 

 

764

 

 

 

 

(2,774

)

 

 

 

699

 

 

 

 

(4,197

)

Total other (expense) income

 

 

 

(187

)

 

 

 

(3,563

)

 

 

 

(2,087

)

 

 

 

(6,359

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Earnings before income taxes

 

 

 

21,154

 

 

 

 

12,265

 

 

 

 

42,597

 

 

 

 

30,387

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Income tax expense

 

 

 

3,357

 

 

 

 

2,171

 

 

 

 

5,829

 

 

 

 

6,432

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net earnings

 

$

 

17,797

 

 

$

 

10,094

 

 

$

 

36,768

 

 

$

 

23,955

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Earnings per share:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic

 

$

 

1.63

 

 

$

 

0.93

 

 

$

 

3.38

 

 

$

 

2.21

 

Diluted

 

$

 

1.61

 

 

$

 

0.93

 

 

$

 

3.35

 

 

$

 

2.21

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Shares used in computing earnings per share:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic

 

 

 

10,907

 

 

 

 

10,835

 

 

 

 

10,879

 

 

 

 

10,818

 

Diluted

 

 

 

11,033

 

 

 

 

10,877

 

 

 

 

10,967

 

 

 

 

10,854

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cash dividends declared per share

$

0.33

$

0.32

$

0.97

$

0.94

 
 
 
 
 

LINDSAY CORPORATION AND SUBSIDIARIES

 

SUMMARY OPERATING RESULTS

 

(Unaudited)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three months ended

 

 

 

Nine months ended

 

(in thousands)

 

 

May 31,

2021

 

 

 

May 31,

2020

 

 

 

May 31,

2021

 

 

 

May 31,

2020

 

Operating revenues:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Irrigation:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

North America

 

$

 

87,364

 

 

$

 

62,895

 

 

 

 

220,332

 

 

$

 

183,570

 

International

 

 

 

52,812

 

 

 

 

32,606

 

 

 

 

125,772

 

 

 

 

88,751

 

Irrigation segment

 

 

 

140,176

 

 

 

 

95,501

 

 

$

 

346,104

 

 

$

 

272,321

 

Infrastructure segment

 

 

 

21,760

 

 

 

 

27,605

 

 

 

 

67,894

 

 

 

 

73,966

 

Total operating revenues

 

$

 

161,936

 

 

$

 

123,106

 

 

$

 

413,998

 

 

$

 

346,287

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating income (loss):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Irrigation segment

 

$

 

23,925

 

 

$

 

15,417

 

 

$

 

52,603

 

 

$

 

35,282

 

Infrastructure segment

 

 

 

3,767

 

 

 

 

8,157

 

 

 

 

14,364

 

 

 

 

22,788

 

Corporate

 

 

 

(6,351

)

 

 

 

(7,746

)

 

 

 

(22,283

)

 

 

 

(21,324

)

Total operating income

 

$

 

21,341

 

 

$

 

15,828

 

 

$

 

44,684

 

 

$

 

36,746

 

 

The Company manages its business activities in two reportable segments as follows:

Irrigation This reporting segment includes the manufacture and marketing of center pivot, lateral move and hose reel irrigation systems and large diameter steel tubing as well as various innovative technology solutions such as GPS positioning and guidance, variable rate irrigation, remote irrigation management and scheduling technology, irrigation consulting and design and industrial IoT solutions.

Infrastructure – This reporting segment includes the manufacture and marketing of moveable barriers, specialty barriers, crash cushions and end terminals, and road marking and road safety equipment.

Certain immaterial reclassifications have been made to the prior year operating results to conform with current year presentation, as revenues and operating income from certain product lines previously included within the Infrastructure reporting segment are now included within the Irrigation reporting segment.

 
 
 
 
 

LINDSAY CORPORATION AND SUBSIDIARIES

 

CONDENSED CONSOLIDATED BALANCE SHEETS

 

(Unaudited)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(in thousands)

 

May 31,

2021

 

 

May 31,

2020

 

 

August 31,

2020

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

ASSETS

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

 

120,801

 

 

$

 

102,474

 

 

$

 

121,403

 

Marketable securities

 

 

 

19,663

 

 

 

 

19,012

 

 

 

 

19,511

 

Receivables, net

 

 

 

107,713

 

 

 

 

84,931

 

 

 

 

84,604

 

Inventories, net

 

 

 

136,601

 

 

 

 

113,301

 

 

 

 

104,792

 

Other current assets, net

 

 

 

32,947

 

 

 

 

19,469

 

 

 

 

17,625

 

Total current assets

 

 

 

417,725

 

 

 

 

339,187

 

 

 

 

347,935

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Property, plant, and equipment, net

 

 

 

92,517

 

 

 

 

72,827

 

 

 

 

79,581

 

Intangibles, net

 

 

 

21,893

 

 

 

 

24,053

 

 

 

 

23,477

 

Goodwill

 

 

 

68,134

 

 

 

 

67,635

 

 

 

 

68,004

 

Operating lease right-of-use assets

 

 

 

19,360

 

 

 

 

27,663

 

 

 

 

27,457

 

Deferred income tax assets

 

 

 

10,247

 

 

 

 

11,118

 

 

 

 

9,935

 

Other noncurrent assets, net

 

 

 

12,341

 

 

 

 

15,003

 

 

 

 

14,137

 

Total assets

 

$

 

642,217

 

 

$

 

557,486

 

 

$

 

570,526

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

LIABILITIES AND SHAREHOLDERS’ EQUITY

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Accounts payable

 

$

 

49,351

 

 

$

 

35,310

 

 

$

 

29,554

 

Current portion of long-term debt

 

 

 

216

 

 

 

 

195

 

 

 

 

195

 

Other current liabilities

 

 

 

94,589

 

 

 

 

71,712

 

 

 

 

72,646

 

Total current liabilities

 

 

 

144,156

 

 

 

 

107,217

 

 

 

 

102,395

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Pension benefits liabilities

 

 

 

6,086

 

 

 

 

5,787

 

 

 

 

6,374

 

Long-term debt

 

 

 

115,557

 

 

 

 

115,723

 

 

 

 

115,682

 

Operating lease liabilities

 

 

 

19,369

 

 

 

 

26,333

 

 

 

 

25,862

 

Deferred income tax liabilities

 

 

 

881

 

 

 

 

835

 

 

 

 

889

 

Other noncurrent liabilities

 

 

 

19,995

 

 

 

 

18,633

 

 

 

 

20,806

 

Total liabilities

 

 

 

306,044

 

 

 

 

274,528

 

 

 

 

272,008

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Shareholders’ equity:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Preferred stock

 

 

 

 

 

 

 

 

 

 

 

 

Common stock

 

 

 

18,991

 

 

 

 

18,918

 

 

 

 

18,918

 

Capital in excess of stated value

 

 

 

85,257

 

 

 

 

76,188

 

 

 

 

77,686

 

Retained earnings

 

 

 

525,926

 

 

 

 

488,518

 

 

 

 

499,724

 

Less treasury stock – at cost

 

 

 

(277,238

)

 

 

 

(277,238

)

 

 

 

(277,238

)

Accumulated other comprehensive loss, net

 

 

 

(16,763

)

 

 

 

(23,428

)

 

 

 

(20,572

)

Total shareholders’ equity

 

 

 

336,173

 

 

 

 

282,958

 

 

 

 

298,518

 

Total liabilities and shareholders’ equity

 

$

 

642,217

 

 

$

 

557,486

 

 

$

 

570,526

 

 
 
 
 
 

LINDSAY CORPORATION AND SUBSIDIARIES

 

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

 

(Unaudited)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Nine months ended

 

(in thousands)

 

 

May 31, 2021

 

 

 

May 31, 2020

 

CASH FLOWS FROM OPERATING ACTIVITIES:

 

 

 

 

 

 

 

 

 

 

Net earnings

 

$

 

36,768

 

 

$

 

23,955

 

Adjustments to reconcile net earnings to net cash provided by operating activities:

 

 

 

 

 

 

 

 

 

 

Depreciation and amortization

 

 

 

14,688

 

 

 

 

14,146

 

Gain on sale of assets held-for-sale

 

 

 

 

 

 

 

(1,191

)

Provision for uncollectible accounts receivable

 

 

 

304

 

 

 

 

466

 

Deferred income taxes

 

 

 

205

 

 

 

 

27

 

Share-based compensation expense

 

 

 

5,021

 

 

 

 

4,118

 

Unrealized foreign currency transaction (gain) loss

 

 

 

(1,934

)

 

 

 

3,632

 

Other, net

 

 

 

(2,123

)

 

 

 

1,575

 

Changes in assets and liabilities:

 

 

 

 

 

 

 

 

 

 

Receivables

 

 

 

(22,934

)

 

 

 

(11,379

)

Inventories

 

 

 

(28,612

)

 

 

 

(23,765

)

Other current assets

 

 

 

(14,025

)

 

 

 

(6,681

)

Accounts payable

 

 

 

20,828

 

 

 

 

5,385

 

Other current liabilities

 

 

 

20,149

 

 

 

 

14,485

 

Other noncurrent assets and liabilities

 

 

 

2,325

 

 

 

 

(8,810

)

Net cash provided by operating activities

 

 

 

30,660

 

 

 

 

15,963

 

 

 

 

 

 

 

 

 

 

 

 

CASH FLOWS FROM INVESTING ACTIVITIES:

 

 

 

 

 

 

 

 

 

 

Purchases of property, plant, and equipment

 

 

 

(22,532

)

 

 

 

(12,268

)

Proceeds from sale of property and equipment held-for-sale

 

 

 

 

 

 

 

3,955

 

Purchases of marketable securities available-for-sale

 

 

 

(13,067

)

 

 

 

(23,389

)

Proceeds from maturities of marketable securities available-for-sale

 

 

 

12,592

 

 

 

 

4,320

 

Acquisition of business, net of cash acquired

 

 

 

 

 

 

 

(3,034

)

Other investing activities, net

 

 

 

(1,960

)

 

 

 

1,503

 

Net cash used in investing activities

 

 

 

(24,967

)

 

 

 

(28,913

)

 

 

 

 

 

 

 

 

 

 

 

CASH FLOWS FROM FINANCING ACTIVITIES:

 

 

 

 

 

 

 

 

 

 

Proceeds from exercise of stock options

 

 

 

3,892

 

 

 

 

1,545

 

Common stock withheld for payroll tax obligations

 

 

 

(1,269

)

 

 

 

(1,111

)

Principal payments on long-term debt

 

 

 

(141

)

 

 

 

(174

)

Dividends paid

 

 

 

(10,566

)

 

 

 

(10,177

)

Net cash used in financing activities

 

 

 

(8,084

)

 

 

 

(9,917

)

 

 

 

 

 

 

 

 

 

 

 

Effect of exchange rate changes on cash and cash equivalents

 

 

 

1,789

 

 

 

 

(1,863

)

Net change in cash and cash equivalents

 

 

 

(602

)

 

 

 

(24,730

)

Cash and cash equivalents, beginning of period

 

 

 

121,403

 

 

 

 

127,204

 

Cash and cash equivalents, end of period

 

$

 

120,801

 

 

$

 

102,474

 

 
 

 

LINDSAY CORPORATION:

Brian Ketcham

Senior Vice President & Chief Financial Officer

402-827-6579

THREE PART ADVISORS:

Hala Elsherbini

214-442-0016

KEYWORDS: United States North America Nebraska

INDUSTRY KEYWORDS: Engineering Manufacturing Agriculture Natural Resources Other Manufacturing Steel

MEDIA:

ITT Announces Sale of Subsidiary Holding Legacy Liabilities to Delticus, an Affiliate of Warburg Pincus

ITT Announces Sale of Subsidiary Holding Legacy Liabilities to Delticus, an Affiliate of Warburg Pincus

  • Divests all asbestos obligations and related insurance assets
  • Stronger annual free cash flow generation from removal of asbestos-related payments
  • Focused on core business and accelerating capital deployment

WHITE PLAINS, N.Y.–(BUSINESS WIRE)–
July 1, 2021– ITT Inc. (NYSE: ITT) today announced that it has divested InTelCo Management LLC (“InTelCo”), a wholly owned subsidiary that holds long-term liabilities including asbestos liabilities and related insurance assets, to Delticus HoldCo, L.P. (“Delticus”), a corporate liability consolidation vehicle and portfolio company of Warburg Pincus LLC, a leading global private equity firm.

“Today’s announcement represents the culmination of our multi-year strategy to reduce ITT’s legacy liability profile,” said Luca Savi, ITT President and CEO. “This transaction, along with our successful U.S. pension plan termination executed in October 2020, position us very favorably for future growth and capital flexibility.”

Savi continued, “The transaction allows ITT to permanently divest its legacy asbestos liabilities and transfer these to a high-quality partner in Delticus. ITT will operate with a simplified and well-capitalized balance sheet, a heightened focus on our core business, including our sustainability initiatives, and without the risks and management time required to manage long-term asbestos liabilities. Going forward ITT will be able to more effectively invest capital and future cash flows into product innovation and organic and inorganic growth initiatives.”

The estimated impact of the divesture will be a one-time after-tax loss of approximately $27 million to be recorded in the second quarter of 2021 and excluded from adjusted earnings per share.

Transaction Overview

Delticus has acquired 100% of the equity of InTelCo, which indemnifies ITT for all legacy asbestos liabilities. At closing, ITT contributed approximately $398 million in cash to InTelCo. As a result of the transaction, ITT removed all asbestos obligations, related insurance assets and associated deferred tax assets from the company’s consolidated balance sheet.

Delticus will assume the operational management of InTelCo, including the administration of all the asbestos claims and collection of existing insurance policy reimbursements.

Evercore acted as exclusive financial advisor to ITT in connection with the transaction, and Simpson Thacher & Bartlett LLP served as its legal counsel. Jefferies acted as exclusive financial advisor to Delticus, and Kirkland & Ellis LLP served as its legal counsel.

Background on InTelCo

In 2016, ITT established InTelCo Management LLC through a corporate reorganization to hold all of the ITT LLC and Goulds Pumps LLC legacy asbestos liabilities and related insurance assets. The reorganization allowed ITT to more efficiently manage liabilities and insurance assets under a single, well-capitalized entity with its own focused management team. The InTelCo team has extensive experience leading litigation defense and insurance litigation and recovery and will continue in its current capacity as part of Delticus. This structure will provide significant operational and financial efficiencies following the sale.

About Delticus

Delticus is a leading institutionally capitalized corporate liability consolidation vehicle, focused on acquiring and managing long-tail legacy corporate liabilities of various forms. Headquartered in Wilmington, DE but operating globally, Delticus offers holders of various forms of corporate liabilities a full risk transfer through an outright corporate sale. Delticus is a portfolio company of Warburg Pincus, a leading global private equity firm, with a 30+ year track record in financial services investing. For more information, please visit www.delticusgroup.com.

About ITT

ITT is a diversified leading manufacturer of highly engineered critical components and customized technology solutions for the transportation, industrial, and oil and gas markets. Building on its heritage of innovation, ITT partners with its customers to deliver enduring solutions to the key industries that underpin our modern way of life. ITT is headquartered in White Plains, N.Y., with employees in more than 35 countries and sales in approximately 125 countries.

Safe Harbor Statement

This release contains “forward-looking statements” intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements are not historical facts, but rather are based on current expectations, estimates, assumptions and projections about our business, future financial results and the industry in which we operate, and other legal, regulatory and economic developments. These forward-looking statements include, but are not limited to, future strategic plans and other statements that describe the company’s business strategy, outlook, objectives, plans, intentions or goals, and any discussion of future events and future operating or financial performance.

We use words such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe,” “target,” “future,” “may,” “will,” “could,” “should,” “potential,” “continue,” “guidance” and other similar expressions to identify such forward-looking statements. Forward-looking statements are uncertain and to some extent unpredictable, and involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from those expressed or implied in, or reasonably inferred from, such forward-looking statements.

Where in any forward-looking statement we express an expectation or belief as to future results or events, such expectation or belief is based on current plans and expectations of our management, expressed in good faith and believed to have a reasonable basis. However, there can be no assurance that the expectation or belief will occur or that anticipated results will be achieved or accomplished.

Among the factors that could cause our results to differ materially from those indicated by forward-looking statements are risks and uncertainties inherent in our business including, without limitation: impacts on our business due to the COVID-19 pandemic, including disruptions to our operations and demand for our products, increased costs, disruption of supply chain and other constraints in the availability of key commodities and other necessary services, government-mandated site closures, employee illness or loss of key personnel, the impact of travel restrictions and stay-in-place restrictions on our business and workforce, customer and supplier bankruptcies, impacts to the global economy and financial markets, and liquidity challenges in accessing capital markets; uncertain global economic and capital markets conditions, including due to COVID-19, trade disputes between the U.S. and its trading partners, and fluctuations in oil prices; risks due to our operations and sales outside the U.S. and in emerging markets; fluctuations in foreign currency exchange rates; fluctuations in demand or customers’ levels of capital investment and maintenance expenditures, especially in the oil and gas, chemical, and mining markets, or changes in our customers’ anticipated production schedules, especially in the commercial aerospace market; failure to compete successfully and innovate in our markets; the extent to which there are quality problems with respect to manufacturing processes or finished goods; risks related to government contracting, including changes in levels of government spending and regulatory and contractual requirements applicable to sales to the U.S. government; volatility in raw material prices and our suppliers’ ability to meet quality and delivery requirements; failure to manage the distribution of products and services effectively; loss of or decrease in sales from our most significant customers; fluctuations in our effective tax rate; failure to protect our intellectual property rights or violations of the intellectual property rights of others; the risk of material business interruptions, particularly at our manufacturing facilities; the risk of cybersecurity breaches; changes in laws relating to the use and transfer of personal and other information; failure of portfolio management strategies, including cost-saving initiatives, to meet expectations; risk of liabilities from past divestitures and spin-offs; changes in environmental laws or regulations, discovery of previously unknown or more extensive contamination, or the failure of a potentially responsible party to perform; failure to comply with the U.S. Foreign Corrupt Practices Act or other applicable anti-corruption legislation, export controls and trade sanctions, including recently announced tariffs; and risk of product liability claims and litigation. More information on factors that could cause actual results or events to differ materially from those anticipated is included in our reports filed with the Securities and Exchange Commission (SEC), including our Annual Report on Form 10-K for the year ended December 31, 2020 (particularly under the caption “Risk Factors”), our Quarterly Reports on Form 10-Q and in other documents we file from time to time with the SEC.

The forward-looking statements included in this release speak only as of the date hereof. We undertake no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Contact

Mark Macaluso

+1 914-641-2064

[email protected]

Delticus Group

[email protected]

KEYWORDS: United States North America New York

INDUSTRY KEYWORDS: Chemicals/Plastics Automotive Manufacturing Aerospace Data Management Manufacturing Technology Air Transport Telecommunications Textiles Steel Packaging Internet Mobile/Wireless Engineering

MEDIA:

Logo
Logo

McCormick Reports Strong Second Quarter Sales Growth And Increases 2021 Financial Outlook

PR Newswire

HUNT VALLEY, Md., July 1, 2021 /PRNewswire/ — McCormick & Company, Incorporated (NYSE:MKC), a global leader in flavor, today reported financial results for the second quarter ended May 31, 2021.

  • Sales rose 11% in the second quarter from the year-ago period. In constant currency, the Company grew sales 8%.
     
  • Operating income was $237 million in the second quarter compared to $257 million in the year-ago period. Adjusted operating income was $258 million compared to $260 million in the second quarter of 2020.
     
  • Earnings per share was $0.68 in the second quarter as compared to $0.73 in the year-ago period. Adjusted earnings per share was $0.69 compared to $0.74 in the year-ago period reflecting a higher adjusted income tax rate versus the second quarter of 2020.
     
  • For fiscal year 2021, McCormick increased its sales outlook to expected growth of 11% to 13%, or 8% to 10% in constant currency, and also raised its operating profit and earnings per share growth outlook.

Chairman, President & CEO’s Remarks

Lawrence E. Kurzius, Chairman, President and CEO, stated, “The combination of McCormick’s broad and advantaged portfolio, the acceleration of consumer trends which our strategies capitalize on and our two recent acquisitions, as well as the effective execution of our strategies and engagement of our employees have positioned us well to drive differentiated growth, even when lapping challenging year-over-year comparisons. We grew sales 11% in the second quarter and, notably, on a two-year basis, sales and adjusted operating income grew 20%, which reflects our robust growth momentum. 

“Our second quarter results were strong compared to our exceptional 2020 second quarter performance. Last year, our Consumer segment demand was driven by a surge of consumers cooking more at home at the onset of the pandemic, while our Flavor Solutions demand was impacted by the substantial decline in away-from-home consumption. Our results reflect cycling these comparisons as well as a sustained shift to consumer at-home consumption higher than pre-pandemic levels and the strong recovery of demand from away-from-home customers. Taken together, these impacts continue to demonstrate the strength and diversity of our offering and we are confident our balanced and diverse portfolio will continue to differentiate McCormick and sustainably position us for long-term growth. 

“Our focus on long-term sustainable growth and propelling our business forward is the foundation of our future. We are capitalizing on accelerating consumer trends, particularly the sustained shift to cooking more at home, increased digital engagement, clean and flavorful eating, and trusted brands, which we are confident will continue to persist even beyond the pandemic. The investments we have made, including in our supply chain resiliency and brand marketing, provide a foundation for growth while enhancing our agility and our relevance with our consumers and customers. With our strong year-to-date results and robust operating momentum, we are entering the second half of our year well positioned to deliver another year of differentiated growth in 2021. Our fundamentals, momentum and growth outlook are stronger than ever. 

“I want to recognize McCormick employees around the world as the collective power of our people drives our momentum and our success. With our vision to stand together for flavor and our relentless focus on growth, performance and people, we are confident our strategies will enable us to become even better positioned to drive future growth and build long-term value for our shareholders.”

Second Quarter 2021 Results

McCormick reported an 11% sales increase in the second quarter from the year-ago period, including a 3% favorable impact from currency. Sales from Cholula and FONA, acquired in November 2020 and December 2020, respectively, added 5% to the sales increase. Flavor Solutions segment sales increased 39%, or 34% in constant currency, driven by higher sales of away-from-home products, incremental sales from acquisitions, as well as growth with packaged food and beverage companies. Consumer segment sales declined 2%, including a 3% favorable impact from currency against a strong comparison of 26% growth in the second quarter of 2020. Despite the difficult year-over-year comparison, Consumer segment sales reflect the sustained shift to consumers cooking more at home, fueled by the Company’s brand marketing, strong digital engagement and new products, as well as acquisition growth.

Gross profit margin declined 190 basis points versus the year-ago period driven by unfavorable product mix and higher cost inflation, partially offset by cost savings led by the Company’s Comprehensive Continuous Improvement (CCI) program. Operating income was $237 million in the second quarter of 2021 compared to $257 million in the year-ago period. This decline included $7 million of transaction expenses related to the acquisitions of Cholula and FONA as well as $14 million of special charges versus $3 million in the second quarter of last year. Excluding transaction and integration expenses as well as special charges, adjusted operating income declined 1% to $258 million in the second quarter compared to $260 million in the year-ago period, or a 4% decline in constant currency. The favorable impact of higher sales and CCI-led cost savings was more than offset by gross margin compression and higher planned brand marketing investments.

Earnings per share was $0.68 in the second quarter of 2021 compared to $0.73 in the second quarter of 2020. The net impact of the gain on the sale of the Company’s minority stake in Eastern Condiments Private Ltd (Eastern), transaction and integration expenses, and special charges lowered earnings per share by $0.01 in the second quarter of 2021. Special charges lowered earnings per share by $0.01 in the second quarter of 2020. Excluding these impacts, adjusted earnings per share was $0.69 in the second quarter of 2021 compared to $0.74 in the year-ago period. This 7% decrease in adjusted earnings per share was driven primarily by a higher adjusted income tax rate.

Year-to-date net cash provided by operating activities was $229 million compared to $356 million through the second quarter of 2020. The decrease was primarily due to the timing associated with working capital payments, including transaction and integration expenses.

Fiscal Year 2021 Financial Outlook

McCormick is capitalizing on the sustained shift to cooking more at home and the growing consumer interests in clean and flavorful eating, increased digital engagement, trusted brands and purpose-minded practices. These long-term trends have accelerated during the COVID-19 pandemic and are expected to persist beyond the pandemic. The Company expects the shift in consumer demand to at-home consumption to be sustained at higher than pre-pandemic levels, as well as a gradual recovery in the demand from restaurant and other foodservice customers which have been impacted by the curtailment of away-from-home dining. McCormick is well positioned for continued growth through the combination of its alignment with these consumer trends, the breadth and reach of its flavor portfolio and its effective growth strategies.

For the fiscal year 2021, McCormick increased its financial outlook for sales, adjusted operating income and adjusted earnings per share based on the Company’s strong year-to-date performance and robust operating momentum. The Company now expects a three-percentage point favorable impact from currency rates on sales and reaffirms the two-percentage point favorable impact from currency on adjusted operating income and adjusted earnings per share.

In 2021, the Company expects to grow sales by 11% to 13% compared to 2020, which in constant currency is 8% to 10% and includes the incremental impact of the Cholula and FONA acquisitions. This is an increase from the Company’s previous projection of 8% to 10%, or 6% to 8% in constant currency. McCormick expects to drive organic sales growth in both its Consumer and Flavor Solutions segments in 2021 driven by brand marketing, new products, category management and differentiated customer engagement. Sales growth is also expected to include the impact of pricing actions taken to partially offset an anticipated mid-single digit increase in costs, previously estimated to be a low-single digit increase.

Operating income in 2021 is expected to grow by 6% to 8% from $1.0 billion in 2020. The Company anticipates transaction and integration expenses related to the Cholula and FONA acquisitions of approximately $42 million in 2021. In addition, McCormick currently expects approximately $21 million of special charges in 2021 that relate to previously announced organization and streamlining actions. Excluding the impact of transaction and integration expenses as well as special charges in 2021 and 2020, adjusted operating income is expected to grow by 10% to 12%, which in constant currency is 8% to 10%. This is an increase from the Company’s previous projection of 9% to 11%, or 7% to 9% in constant currency. This expected growth range includes strong base business growth and acquisition contribution partially offset by a 4% impact from incremental 2021 business transformation and first-half volume driven COVID-19 expenses.

McCormick increased its projected 2021 earnings per share to be in the range of $2.83 to $2.88, compared to $2.78 of earnings per share in 2020. The Company expects the net impact of the transaction and integration expenses, including an unfavorable income tax expense impact from a discrete item related to the acquisition of FONA, as well as special charges and the gain on the sale of the Company’s minority stake in Eastern to lower earnings per share by $0.17 in 2021. Excluding these impacts, the Company projects 2021 adjusted earnings per share to be in the range of $3.00 to $3.05. This is an increase from previously reported guidance of $2.97 to $3.02, and, as compared to $2.83 of adjusted earnings per share in 2020, represents an expected increase of 6% to 8%, which includes a favorable impact from currency. This reflects strong base business growth and acquisition contribution, partially offset by a 4% impact from incremental 2021 business transformation and COVID-19 expenses and a 4% headwind from an anticipated increase in the projected adjusted effective tax rate to approximately 23%.

For fiscal year 2021, the Company projects another year of strong cash flow, with plans to return a significant portion to McCormick’s shareholders through dividends and to pay down debt.

Business Segment Results

Consumer Segment

(in millions)


Three months ended


Six months ended


5/31/2021

5/31/2020


5/31/2021

5/31/2020

Net sales


$


945.2

$

962.6


$


1,892.0

$

1,662.1

Operating income, excluding special 
     charges, transaction and integration

     expenses


176.8

231.6


366.7

351.2

The Consumer segment sales declined 2% from the second quarter of 2020, which includes a 2% increase from the Cholula acquisition. In constant currency, sales declined 5%, due to the exceptionally high demand for McCormick products in the year-ago period driven by the surge of consumers cooking more at home at the onset of the COVID-19 pandemic.

  • Consumer sales in the Americas decreased 6% compared to the second quarter of 2020, including a 3% increase from the Cholula acquisition. In constant currency, sales decreased 7% due to lapping the surge in demand in the year-ago period.
     
  • Consumer sales in Europe, Middle East and Africa (EMEA) rose 4% compared to the year-ago period, including an 8% favorable impact from currency. In constant currency, sales declined 4% due to the exceptionally high demand in the year-ago period.
     
  • Consumer sales in the Asia/Pacific region increased 26% compared to the year-ago period. In constant currency, sales increased 15% driven by the products related to away-from-home consumption in McCormick’s portfolio, mainly due to the recovery from the extended lockdown in China’sHubei province in the year-ago period. Partially offsetting this increase were declines of cooking at-home products across the region due to elevated demand in the year-ago period.

Consumer segment operating income, excluding transaction and integration expenses, as well as special charges, decreased 24% to $177 million for the second quarter of 2021 compared to $232 million in the year-ago period. In constant currency, Consumer operating income decreased 26%. The decline was driven by lower sales, higher cost inflation and a 16% increase in brand marketing, partially offset by favorable product mix and CCI-led cost savings. Additionally, the Consumer segment’s operating income margin had a significant unfavorable impact from the deleveraging of fixed costs resulting from lower sales.

Flavor Solutions Segment

(in millions)


Three months ended


Six months ended


5/31/2021

5/31/2020


5/31/2021

5/31/2020

Net sales


$


611.5

$

438.5


$


1,146.2

$

951.0

Operating income, excluding special 
     charges, transaction and integration

     expenses


81.2

28.7


153.8

104.3

Flavor Solutions segment sales increased 39% in the second quarter, with the FONA and Cholula acquisitions contributing 9% to that increase. In constant currency, sales increased 35% driven primarily by higher sales to our restaurant and other foodservice customers as away-from-home dining was significantly curtailed in the year-ago period.

  • In the Americas, Flavor Solutions sales rose 32% compared to the second quarter of 2020, with the FONA and Cholula acquisitions contributing 13% to that increase. In constant currency, sales increased 30% from the year-ago period driven by higher sales to branded foodservice customers as well as continued growth with packaged food and beverage companies.
     
  • The EMEA region’s Flavor Solutions sales increased 78% compared to the second quarter of 2020, and in constant currency grew 65%. Higher sales to quick service restaurants and branded foodservice customers combined with strong growth with packaged food companies drove the increase.
     
  • The Asia/Pacific region’s Flavor Solutions sales grew 36% compared to the second quarter of 2020. In constant currency, sales increased 23%. This increase was led by growth with quick service restaurants in addition to recovery from COVID-19 related lockdowns in the year-ago period.

Flavor solutions segment operating income, excluding transaction and integration expenses, as well as special charges, increased 183% to $81 million for the second quarter of 2021 compared to $29 million in the year-ago period. In constant currency, Flavor Solutions operating income increased 175%. Higher sales, favorable product mix and CCI-led cost savings more than offset higher cost inflation. Additionally, the leverage of fixed costs resulting from higher sales also had a significant favorable impact on Flavor Solutions segment’s operating income margin.

Non-GAAP Financial Measures

The tables below include financial measures of adjusted gross profit, adjusted gross profit margin, adjusted operating income, adjusted operating income margin, adjusted income tax expense, adjusted income tax rate, adjusted net income and adjusted diluted earnings per share. These represent non-GAAP financial measures which are prepared as a complement to our financial results prepared in accordance with United States generally accepted accounting principles. These financial measures exclude the impact, as applicable, of the following:

Special charges – In our consolidated income statement, we include a separate line item captioned “Special charges” in arriving at our consolidated operating income. Special charges consist of expenses associated with certain actions undertaken by the company to reduce fixed costs, simplify or improve processes, and improve our competitiveness and are of such significance in terms of both up-front costs and organizational/structural impact to require advance approval by our Management Committee. Upon presentation of any such proposed action (including details with respect to estimated costs, expected benefits and expected timing) to the Management Committee and the Committee’s advance approval, expenses associated with the approved action are classified as special charges upon recognition and monitored on an on-going basis through completion.

Transaction and integration expenses associated with the Cholula and FONA acquisitions – We exclude certain costs associated with our acquisitions of Cholula and FONA in November and December 2020, respectively, and their subsequent integration into the Company. Such costs, which we refer to as “Transaction and integration expenses”, include transaction costs associated with the acquisition, as well as integration costs following the acquisition, including the impact of any acquisition date fair value adjustment for inventory, together with the impact of discrete tax items, if any, directly related to each acquisition.

Income from sale of unconsolidated operations – We exclude the gain realized with our sale of an unconsolidated operation in March 2021 that occurred during the second quarter of fiscal 2021. The sale of our 26% interest in Eastern Condiments Private Ltd resulted in a gain of $13.4 million, net of tax of $5.7 million. The gain is included in Income from unconsolidated operations in our consolidated income statement.

We believe that these non-GAAP financial measures are important. The exclusion of the items noted above provides additional information that enables enhanced comparisons to prior periods and, accordingly, facilitates the development of future projections and earnings growth prospects. This information is also used by management to measure the profitability of our ongoing operations and analyze our business performance and trends.

These non-GAAP financial measures may be considered in addition to results prepared in accordance with GAAP, but they should not be considered a substitute for, or superior to, GAAP results. In addition, these non-GAAP financial measures may not be comparable to similarly titled measures of other companies because other companies may not calculate them in the same manner that we do. We intend to continue to provide these non-GAAP financial measures as part of our future earnings discussions and, therefore, the inclusion of these non-GAAP financial measures will provide consistency in our financial reporting. A reconciliation of these non-GAAP financial measures to the related GAAP financial measures is provided below:

(in millions except per share data)

Three Months Ended

Six Months Ended


5/31/2021

5/31/2020


5/31/2021

5/31/2020

Gross profit


$


614.6

$

579.5


$


1,192.1

$

1,049.4

Impact of transaction and integration expenses included in cost of goods sold (1)




6.3

Adjusted gross profit


$


614.6

$

579.5


$


1,198.4

$

1,049.4

Adjusted gross profit margin (2)


39.5


%

41.4

%


39.4


%

40.2

%

Operating income


$


237.4

$

257.4


$


473.7

$

451.6

Impact of transaction and integration expenses included in cost of goods sold (1)




6.3

Impact of other transaction and integration expenses (1)


6.9


25.7

Impact of special charges


13.7

2.9


14.8

3.9

Adjusted operating income


$


258.0

$

260.3


$


520.5

$

455.5

% increase versus year-ago period


(0.9)


%


14.3


%

Adjusted operating income margin (3)


16.6


%

18.6

%


17.1


%

17.4

%

Income tax expense


$


45.4

$

40.4


$


104.0

$

70.5

Impact of transaction and integration expenses (1)


1.6


(4.3)

Impact of special charges


3.2

0.9


3.5

1.2

Adjusted income tax expense


$


50.2

$

41.3


$


103.2

$

71.7

Adjusted income tax rate (4)


22.2


%

18.0

%


22.5


%

18.2

%

Net income


$


183.7

$

195.9


$


345.5

$

340.6

Impact of transaction and integration expenses (1)


5.3


36.3

Impact of special charges


10.5

2.0


11.3

2.7

Impact of after-tax gain on sale of unconsolidated operations


(13.4)


(13.4)

Adjusted net income


$


186.1

$

197.9


$


379.7

$

343.3

% (decrease) increase versus year-ago period


(6.0)


%


10.6


%

Earnings per share – diluted


$


0.68

$

0.73


$


1.28

$

1.27

Impact of transaction and integration expenses (1)


0.02


0.14

Impact of special charges


0.04

0.01


0.04

0.01

Impact of after-tax gain on sale of unconsolidated operations


(0.05)


(0.05)

$

Adjusted earnings per share – diluted


$


0.69

$

0.74


$


1.41

$

1.28

% (decrease) increase versus year-ago period


(6.8)


%


10.2


%

(1)

Transaction and integration expenses include transaction and integration expenses associated with our acquisitions of Cholula and FONA. These expenses include transaction expenses, integration expenses, including the effect of the fair value adjustment of acquired inventory on cost of goods sold and the unfavorable impact of a discrete item related to deferred State income tax expense, during the first quarter of 2021, directly related to our December 2020 acquisition of FONA, of $11.4 million or $0.04 per diluted share for the six months ended May 31, 2021.

(2)

Adjusted gross profit margin is calculated as adjusted gross profit as a percentage of net sales for each period presented.

(3)

Adjusted operating income margin is calculated as adjusted operating income as a percentage of net sales for each period presented.

(4)

Adjusted income tax rate is calculated as adjusted income tax expense as a percentage of income from consolidated operations before income taxes excluding transaction and integration expenses and special charges of $226.3 million and $459.6 million for the three and six months ended May 31, 2021, respectively, and $229.0 million and $394.4 million for the three and six months ended May 31, 2020, respectively.

Because we are a multi-national company, we are subject to variability of our reported U.S. dollar results due to changes in foreign currency exchange rates. Those changes have been volatile over the past several years. The exclusion of the effects of foreign currency exchange, or what we refer to as amounts expressed “on a constant currency basis”, is a non-GAAP measure. We believe that this non-GAAP measure provides additional information that enables enhanced comparison to prior periods excluding the translation effects of changes in rates of foreign currency exchange and provides additional insight into the underlying performance of our operations located outside of the U.S. It should be noted that our presentation herein of amounts and percentage changes on a constant currency basis does not exclude the impact of foreign currency transaction gains and losses (that is, the impact of transactions denominated in other than the local currency of any of our subsidiaries in their local currency reported results).

Percentage changes in sales and adjusted operating income expressed on a constant currency basis are presented excluding the impact of foreign currency exchange. To present this information for historical periods, current period results for entities reporting in currencies other than the U.S. dollar are translated into U.S. dollars at the average exchange rates in effect during the corresponding period of the prior fiscal year, rather than at the actual average exchange rates in effect during the current fiscal year. As a result, the foreign currency impact is equal to the current year results in local currencies multiplied by the change in the average foreign currency exchange rate between the current fiscal period and the corresponding period of the prior fiscal year. Rates of constant currency growth (decline) follow:

Three Months Ended May 31, 2021

Percentage Change
as Reported

Impact of Foreign
Currency Exchange

Percentage Change on
Constant Currency
Basis


Net sales


Consumer Segment

  Americas

(6.4)%

0.8%

(7.2)%

  EMEA

3.6%

7.8%

(4.2)%

  Asia/Pacific

25.5%

10.5%

15.0%

Total Consumer segment

(1.8)%

2.9%

(4.7)%


Flavor Solutions segment

  Americas

31.6%

1.9%

29.7%

  EMEA

77.7%

13.0%

64.7%

  Asia/Pacific

35.5%

12.9%

22.6%

Total Flavor Solutions segment

39.5%

4.9%

34.6%


  Total net sales

11.1%

3.5%

7.6%


Adjusted operating income

   Consumer segment

(23.7)%

2.0%

(25.7)%

   Flavor Solutions segment

182.9%

7.9%

175.0%


Total adjusted operating income

(0.9)%

2.7%

(3.6)%

Six Months Ended May 31, 2021

Percentage Change
as Reported

Impact of Foreign
Currency Exchange

Percentage Change on
Constant Currency
Basis


Net sales


Consumer Segment

  Americas

7.9%

0.6%

7.3%

  EMEA

17.8%

8.0%

9.8%

  Asia/Pacific

45.8%

10.1%

35.7%

Total Consumer segment

13.8%

3.1%

10.7%


Flavor Solutions segment

  Americas

16.1%

0.8%

15.3%

  EMEA

32.3%

6.0%

26.3%

  Asia/Pacific

30.5%

10.5%

20.0%

Total Flavor Solutions segment

20.5%

2.7%

17.8%


  Total net sales

16.3%

2.9%

13.4%


Adjusted operating income

   Consumer segment

4.4%

2.9%

1.5%

   Flavor Solutions segment

47.5%

2.3%

45.2%


Total adjusted operating income

14.3%

2.8%

11.5%

To present “constant currency” information for the fiscal year 2021 projection, projected sales and adjusted operating income for entities reporting in currencies other than the U.S. dollar are translated into U.S. dollars at the company’s budgeted exchange rates for 2021 and are compared to the 2020 results, translated into U.S. dollars using the same 2021 budgeted exchange rates, rather than at the average actual exchange rates in effect during fiscal year 2020. To estimate the percentage change in adjusted earnings per share on a constant currency basis, a similar calculation is performed to arrive at adjusted net income divided by historical shares outstanding for fiscal year 2020 or projected shares outstanding for fiscal year 2021, as appropriate.

Projection for the Year Ending November 30, 2021

Percentage change in net sales

11% to 13%

Impact of favorable foreign currency exchange

3%

Percentage change in net sales in constant currency

8% to 10%

Percentage change in adjusted operating income

10% to 12%

Impact of favorable foreign currency exchange

2%

Percentage change in adjusted operating income in constant currency

8% to 10%

Percentage change in adjusted earnings per share — diluted

6% to 8%

Impact of favorable foreign currency exchange

2%

Percentage change in adjusted earnings per share in constant currency — diluted

4% to 6%

The following provides a reconciliation of our estimated earnings per share to adjusted earnings per share for 2021 and actual results for 2020:

Twelve Months Ended

2021 Projection

11/30/20

Earnings per share – diluted

$2.83 to $2.88

$

2.78

Impact of transaction and integration expenses

0.16

0.04

Impact of special charges

0.06

0.01

Impact of unconsolidated investment

(0.05)

Adjusted earnings per share

$3.00 to $3.05

$

2.83

Live Webcast

As previously announced, McCormick will hold a conference call with analysts today at 8:00 a.m. ET. The conference call will be webcast live via the McCormick website. Go to ir.mccormick.com and follow directions to listen to the call and access the accompanying presentation materials. At this same location, a replay of the call will be available following the live call. Past press releases and additional information can be found at this address.

Forward-looking Information

Certain information contained in this release, including statements concerning expected performance, such as those relating to net sales, gross margins, earnings, cost savings, transaction and integration expenses, special charges, acquisitions, brand marketing support, volume and product mix, income tax expense and the impact of foreign currency rates are “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. These statements may be identified by the use of words such as “may,” “will,” “expect,” “should,” “anticipate,” “intend,” “believe” and “plan.” These statements may relate to: the impact of COVID-19 on our business, suppliers, consumers, customers, and employees; disruptions or inefficiencies in the supply chain, including any impact of COVID-19; the expected results of operations of businesses acquired by the company, including the acquisitions of Cholula and FONA; the expected impact of material costs and pricing actions on the company’s results of operations and gross margins; the expected impact of productivity improvements, including those associated with our Comprehensive Continuous Improvement (“CCI”) program and global enablement initiative; expected working capital improvements; expectations regarding growth potential in various geographies and markets, including the impact from customer, channel, category, and e-commerce expansion; expected trends in net sales and earnings performance and other financial measures; the expected timing and costs of implementing our business transformation initiative, which includes the implementation of a global enterprise resource planning (“ERP”) system; the expected impact of accounting pronouncements; the expectations of pension and postretirement plan contributions and anticipated charges associated with those plans; the holding period and market risks associated with financial instruments; the impact of foreign exchange fluctuations; the adequacy of internally generated funds and existing sources of liquidity, such as the availability of bank financing; the anticipated sufficiency of future cash flows to enable the payments of interest and repayment of short- and long-term debt as well as quarterly dividends and the ability to issue additional debt or equity securities; and expectations regarding purchasing shares of McCormick’s common stock under the existing repurchase authorization.

These and other forward-looking statements are based on management’s current views and assumptions and involve risks and uncertainties that could significantly affect expected results. Results may be materially affected by factors such as: the company’s ability to drive revenue growth; damage to the company’s reputation or brand name; loss of brand relevance; increased private label use; product quality, labeling, or safety concerns; negative publicity about our products; actions by, and the financial condition of, competitors and customers; the longevity of mutually beneficial relationships with our large customers; the ability to identify, interpret and react to changes in consumer preferences and demand; business interruptions due to natural disasters, unexpected events or public health crises, including COVID-19; issues affecting the company’s supply chain and raw materials, including fluctuations in the cost and availability of raw and packaging materials;  government regulation, and changes in legal and regulatory requirements and enforcement practices; the lack of successful acquisition and integration of new businesses, including the acquisitions of Cholula and FONA; global economic and financial conditions generally, including the impact of the exit of the United Kingdom from the European Union, availability of financing, interest and inflation rates, and the imposition of tariffs, quotas, trade barriers and other similar restrictions; foreign currency fluctuations; the effects of increased level of debt service following the Cholula and FONA acquisitions as well as the effects that such increased debt service may have on the company’s ability to borrow or the cost of any such additional borrowing, our credit rating, and our ability to react to certain economic and industry conditions; impairments of indefinite-lived intangible assets; assumptions we have made regarding the investment return on retirement plan assets, and the costs associated with pension obligations; the stability of credit and capital markets; risks associated with the company’s information technology systems, including the threat of data breaches and cyber-attacks; the company’s inability to successfully implement our business transformation initiative; fundamental changes in tax laws; including interpretations and assumptions we have made, and guidance that may be issued, volatility in our effective tax rate; climate change; infringement of intellectual property rights, and those of customers; litigation, legal and administrative proceedings; the company’s inability to achieve expected and/or needed cost savings or margin improvements; negative employee relations; and other risks described in the company’s filings with the Securities and Exchange Commission.

Actual results could differ materially from those projected in the forward-looking statements. The company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.

About McCormick

McCormick & Company, Incorporated is a global leader in flavor. As a Fortune 500 company with over $5 billion in annual sales across 160 countries and territories, we manufacture, market and distribute spices, seasoning mixes, condiments and other flavorful products to the entire food industry including e-commerce channels, grocery, food manufacturers and foodservice businesses. Our most popular brands include McCormick, French’s, Frank’s RedHot, Stubb’s, OLD BAY, Lawry’s, Zatarain’s, Ducros, Vahiné, Cholula, Schwartz, Kamis, DaQiao, Club House, Aeroplane and Gourmet Garden. Every day, no matter where or what you eat or drink, you can enjoy food flavored by McCormick.

Founded in 1889 and headquartered in Hunt Valley, Maryland USA, McCormick is guided by our principles and committed to our Purpose – To Stand Together for the Future of Flavor. McCormick envisions A World United by Flavor where healthy, sustainable and delicious go hand in hand. To learn more, visit www.mccormickcorporation.com or follow McCormick & Company on Twitter, Instagram and LinkedIn.

For information contact:

Investor Relations:
Kasey Jenkins (410) 771-7140 or [email protected]

Corporate Communications:
Lori Robinson (410) 527-6004 or [email protected]


(Financial tables follow)

 

Second Quarter Report

McCormick & Company, Incorporated


Consolidated Income Statement (Unaudited)

(In millions except per-share data)

Three months ended

Six months ended


May 31, 2021

May 31, 2020


May 31, 2021

May 31, 2020

Net sales


$


1,556.7

$

1,401.1


$


3,038.2

$

2,613.1

Cost of goods sold


942.1

821.6


1,846.1

1,563.7

Gross profit


614.6

579.5


1,192.1

1,049.4

Gross profit margin


39.5


%

41.4

%


39.2


%

40.2

%

Selling, general and administrative expense


356.6

319.2


677.9

593.9

Transaction and integration expenses


6.9


25.7

Special charges


13.7

2.9


14.8

3.9

Operating income


237.4

257.4


473.7

451.6

Interest expense


35.6

34.4


69.4

69.7

Other income, net


3.9

3.1


8.5

8.6

Income from consolidated operations before income taxes


205.7

226.1


412.8

390.5

Income tax expense


45.4

40.4


104.0

70.5

Net income from consolidated operations


160.3

185.7


308.8

320.0

Income from unconsolidated operations (including, for 2021, after-tax gain of $13.4 on sale of unconsolidated operation)


23.4

10.2


36.7

20.6

Net income


$


183.7

$

195.9


$


345.5

$

340.6

Earnings per share – basic


$


0.69

$

0.74


$


1.29

$

1.28

Earnings per share – diluted


$


0.68

$

0.73


$


1.28

$

1.27

Average shares outstanding – basic


267.3

266.2


267.2

$

266.1

Average shares outstanding – diluted


270.0

268.5


270.0

268.7

 

Second Quarter Report

McCormick & Company, Incorporated


Consolidated Balance Sheet (Unaudited)

(In millions)


May 31, 2021

November 30, 2020


Assets

Cash and cash equivalents


$


291.8

$

423.6

Trade accounts receivable, net


500.4

528.5

Inventories


1,147.8

1,032.6

Prepaid expenses and other current assets


112.6

98.9

Total current assets


2,052.6

2,083.6

Property, plant and equipment, net


1,112.8

1,028.4

Goodwill


5,428.8

4,986.3

Intangible assets, net


3,494.5

3,239.4

Investments and other assets


721.8

752.0

Total assets


$


12,810.5

$

12,089.7


Liabilities

Short-term borrowings and current portion of long-term debt


$


725.0

$

1,150.6

Trade accounts payable


1,040.5

1,032.3

Other accrued liabilities


615.7

863.6

Total current liabilities


2,381.2

3,046.5

Long-term debt


4,735.9

3,753.8

Deferred taxes


742.8

727.2

Other long-term liabilities


609.8

622.2

Total liabilities


8,469.7

8,149.7


Shareholders’ equity

Common stock


2,027.1

1,981.3

Retained earnings


2,660.5

2,415.6

Accumulated other comprehensive loss


(362.3)

(470.8)

Total McCormick shareholders’ equity


4,325.3

3,926.1

Non-controlling interests


15.5

13.9

Total shareholders’ equity


4,340.8

3,940.0

Total liabilities and shareholders’ equity


$


12,810.5

$

12,089.7

 

Second Quarter Report

McCormick & Company, Incorporated


Consolidated Cash Flow Statement (Unaudited)

(In millions)


Six Months Ended


May 31, 2021


May 31, 2020


Operating activities

Net income


$


345.5

$

340.6

Adjustments to reconcile net income to net cash provided by operating activities:

Depreciation and amortization


91.9

81.5

Stock-based compensation


42.6

27.1

Amortization of inventory fair value adjustments associated with acquisitions


6.3

Fixed asset impairment charge


6.5

Income from unconsolidated operations


(36.7)

(20.6)

Changes in operating assets and liabilities


(247.4)

(89.2)

Dividends from unconsolidated affiliates


20.0

16.1

Net cash flow provided by operating activities


228.7

355.5


Investing activities

Acquisition of businesses (net of cash acquired)


(706.4)

Proceeds from sale of unconsolidated operations


65.4

Capital expenditures (including software)


(112.8)

(87.1)

Other investing activities


0.2

1.9

Net cash flow used in investing activities


(753.6)

(85.2)


Financing activities

Short-term borrowings, net


(429.4)

(514.5)

Long-term debt borrowings


1,001.5

495.0

Payment of debt issuance costs


(1.9)

(1.1)

Long-term debt repayments


(3.5)

(41.7)

Proceeds from exercised stock options


6.2

26.7

Taxes withheld and paid on employee stock awards


(13.0)

(9.2)

Common stock acquired by purchase


(0.4)

(20.8)

Dividends paid


(181.6)

(164.9)

Net cash flow provided by (used in) financing activities


377.9

(230.5)

Effect of exchange rate changes on cash and cash equivalents


15.2

(10.2)

(Decrease) increase in cash and cash equivalents


(131.8)

29.6

Cash and cash equivalents at beginning of period


423.6

155.4


Cash and cash equivalents at end of period


$


291.8

$

185.0

 

Cision View original content:https://www.prnewswire.com/news-releases/mccormick-reports-strong-second-quarter-sales-growth-and-increases-2021-financial-outlook-301324164.html

SOURCE McCormick & Company, Incorporated

Immunic, Inc. Announces FDA Clearance to Begin IMU-838 Phase 3 ENSURE Studies in Relapsing-Remitting Multiple Sclerosis and Phase 2 CALLIPER Study in Progressive Multiple Sclerosis

– Phase 3 ENSURE Program in Relapsing-Remitting Multiple Sclerosis (RRMS) Comprises Twin Studies Evaluating Efficacy, Safety, and Tolerability of IMU-838 Versus Placebo, Intended to Provide Straightforward Path to Regulatory Approval –

– Supportive Phase 2 CALLIPER Trial in Progressive Multiple Sclerosis (PMS), Designed to Corroborate IMU-838’s Neuroprotective Potential and Support Differentiated Profile –

– Company Expects Initiation of Both ENSURE and CALLIPER in the Second Half of 2021 –

– Conference Call and Webcast to be Held July 1, 2021 at 8:00 am ET –

PR Newswire

NEW YORK, July 1, 2021 /PRNewswire/ — Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced U.S. Food and Drug Administration (FDA) clearance of its Investigational New Drug (IND) application for the phase 3 ENSURE program of lead asset IMU-838, the company’s selective oral DHODH inhibitor, in patients with relapsing-remitting multiple sclerosis (RRMS). In addition, the FDA also cleared the company’s separate IND application for the supportive phase 2 CALLIPER trial of IMU-838 in patients with progressive multiple sclerosis (PMS).

The ENSURE program comprises two multicenter, randomized, double-blind phase 3 trials designed to evaluate the efficacy, safety, and tolerability of IMU-838 versus placebo in RRMS patients. Based on IMU-838’s robust activity in preventing lesion formation in the company’s phase 2 EMPhASIS trial in RRMS, the strong and consistent correlation observed between lesion formation and clinical relapse in third-party clinical trials, and the drug’s robust safety profile to date, Immunic believes that this phase 3 program provides a simple and straightforward path towards potential regulatory approval of IMU-838 in RRMS.

The multicenter, randomized, double-blind, placebo-controlled phase 2 CALLIPER trial is intended to run concurrently with and to complement the phase 3 program in RRMS. In particular, CALLIPER is focused on progressive forms of multiple sclerosis (MS) and designed to corroborate IMU-838’s neuroprotective potential, as exemplified by slowing of brain atrophy and delay in disability worsening. Neurodegeneration is a key concern in both PMS and RRMS, since axonal and neural damage is responsible for the increasing and often severe disability experienced by patients. Immunic believes that, if the CALLIPER trial is successful in showing a beneficial effect of IMU-838, this data, along with the ENSURE program and IMU-838’s strong safety and tolerability profile, may allow for a meaningful clinical differentiation of IMU-838 from other oral MS medications and an attractive commercial positioning. Although a supportive trial, Immunic does not believe that data from the CALLIPER trial are a pre-condition for filing a New Drug Application in RRMS.

“IMU-838’s phase 2 results in relapsing-remitting multiple sclerosis showed an encouraging balance between efficacy, safety, and tolerability and I look forward to the phase 3 program in this indication,” commented Robert J. Fox, M.D., Staff Neurologist, Mellen Center for Multiple Sclerosis, Vice-Chair for Research, Neurologic Institute, Cleveland Clinic, Cleveland, Ohio, andCoordinating Investigator of the ENSURE and CALLIPER programs. “Disability progression is a principal concern for clinicians and patients of both PMS and RRMS. The ongoing disability worsening, even in periods without relapse, not only diminishes quality-of-life but can also ultimately lead to profound impairments in patient mobility. There is a clear unmet need for new therapeutic options which can help delay or arrest this process and I look forward to seeing data on IMU-838’s neuroprotective potential.” Dr. Fox receives compensation as a chair of the steering committees for the ENSURE and CALLIPER programs.

“IND clearance for our phase 3 program in RRMS is yet another seminal moment for Immunic as it progresses our lead asset, IMU-838, into a pivotal program and heralds the final phase of clinical development in MS. We believe that the phase 3 ENSURE program meaningfully simplifies IMU-838’s regulatory approval path in MS as it applies a very clean and straightforward study design,” stated Daniel Vitt, Ph.D., Chief Executive Officer and President of Immunic. “In addition, together with our MS expert panel, we designed the CALLIPER trial to study patients who currently are not typically treated with relapse preventing therapies. Our goal is to highlight IMU-838 as a therapy that combines truly differentiated safety and tolerability with neuroprotective activity such as slowing of brain atrophy and disability worsening. In our view, success in the CALLIPER trial could provide an important differentiator for IMU-838 in the MS market. We look forward to hopefully providing IMU-838 as an important new therapeutic option to MS patients within the next few years.”

Each of the identical twin phase 3 trials, titled ENSURE-1 and ENSURE-2, is expected to enroll approximately 1,050 adult patients with active RMS at more than 100 sites in 14 countries, including the United States, Latin America, Central and Eastern Europe, and India. Patients will be randomized in a double-blinded fashion to either 30 mg daily doses of IMU-838 or placebo and the primary endpoint for both trials is time to first relapse up to 72 weeks. Key secondary endpoints include volume of new T2-lesions, time to confirmed disability progression, time to sustained clinically relevant changes in cognition, and percentage of whole brain volume change, grey matter volume, and white matter volume. With regard to the disability progression endpoint, the ENSURE program applies a pooled analysis of disability worsening across both trials, which may be further supported by data from the CALLIPER trial.

The ENSURE trials will be run concurrently, with dosing of the first patient expected in the second half of 2021. An interim analysis to assess event rates is planned to occur after a certain number of relapses have occurred in the double-blind treatment periods. This analysis is intended to inform potential sample size adjustment and help ensure that final study readout is not planned to occur before sufficient events have been achieved. This interim analysis is not intended as a futility analysis.

The phase 2 CALLIPER trial is expected to enroll approximately 450 patients at more than 70 sites in North America, Western, Central and Eastern Europe with patients randomized to either 45 mg daily doses of IMU-838 or placebo in a double-blinded fashion. The trial’s primary endpoint is the annualized rate of percent brain volume change up to 120 weeks. Key secondary endpoints include the annualized rate of change in whole brain atrophy and time to 24-week confirmed disability progression based on the expanded disability status scale (EDSS). Dosing of the first patient is expected in the third quarter of 2021.

An interim analysis comprising an unblinded analysis of serum neurofilament light chain (NfL) is planned to occur once approximately half of the enrolled patients have completed 24 weeks of treatment. NfL has been shown consistently to correlate with disease activity in neurological disorders and has become one of the most important serum biomarkers for axonal damage over the past few years. As previously reported, results of the phase 2 EMPhASIS trial of IMU-838 in RRMS showed a robust decrease in serum NfL at 24 weeks (-17.0% for 30 mg and -20.5% for 45 mg), as compared to baseline values, while the patients on placebo experienced a 6.5% increase in serum NfL over the same period.

“The Immunic team is very excited to see IMU-838 progressing into a pivotal program in RRMS. Based on its very strong safety and tolerability profile along with its robust efficacy, which we are planning to further highlight with neuroprotective data from the CALLIPER trial, we believe that IMU-838 has the potential to become a well-differentiated new treatment option for MS patients,” added Andreas Muehler, M.D., Chief Medical Officer of Immunic. “In our discussions with regulatory authorities, including the FDA and the European Medicines Agency, testing IMU-838 against placebo was viewed as a reasonable approach for our phase 3 program, from both a regulatory and scientific perspective, as placebo provides the cleanest comparator to show proof-of-efficacy and to underline IMU-838’s existing safety and tolerability profile.”

Conference Call and Webcast Information

Immunic’s management team will host a public conference call and webcast on July 1, 2021 at 8:00 a.m. Eastern Time to discuss the company’s overall MS development strategy, the phase 3 ENSURE program in RRMS, and the phase 2 CALLIPER trial in PMS.

To participate in the conference call, dial 1-877-870-4263 (USA) or 1-412-317-0790 (International) and ask to be joined into the Immunic, Inc. call. A live, listen-only webcast of the conference call can be accessed at https://www.webcaster4.com/Webcast/Page/2301/39951 or on the “Events and Presentations” section of Immunic’s website at ir.imux.com/events-and-presentations.

An archived replay of conference call and webcast will be available approximately one hour after the completion for one year on Immunic’s website at: ir.imux.com.

About Multiple Sclerosis

Multiple sclerosis (MS) is an autoimmune disease that affects the brain, spinal cord and optic nerve. In MS, myelin, the coating that protects the nerves, is attacked and damaged by the immune system. Thus, MS is considered an immune-mediated demyelinating disease of the central nervous system. MS affects approximately one million people in the United States, and more than 2.8 million people worldwide. The disease mainly affects young adults of prime working age, although MS can occur at any age. MS is at least two to three times more common in women than in men.

Relapsing-remitting MS (RRMS) is the most common form of the disease. Approximately 85% of patients with MS are expected to develop RRMS, with some of these patients later developing more progressive forms of the disease. RRMS is characterized by clearly defined attacks of new or increasing neurologic symptoms. These relapses are followed by periods of remission, or partial or complete recovery. During remissions, all symptoms may disappear, or some symptoms may continue and become permanent. MS is a progressive disease which, without effective treatment, leads to severe disability.

Progressive MS (PMS) includes both primary progressive MS (PPMS) and secondary progressive MS (SPMS). PPMS is characterized by steadily worsening neurologic function from the onset of symptoms without initial relapse or remissions. SPMS is identified following an initial relapsing remitting course, after which the disease becomes more steadily progressive, with or without other disease activity present.

About IMU-838

IMU-838 is an orally available, next-generation selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme dihydroorotate dehydrogenase (DHODH). IMU-838 acts on activated T and B cells while leaving other immune cells largely unaffected and allows the immune system to stay functioning, e.g. in fighting infections. In previous trials, IMU-838 did not show an increased rate of infections compared to placebo. In addition, DHODH inhibitors, such as IMU-838, are known to possess a host-based antiviral effect, which is independent with respect to specific virus proteins and their structure. Therefore, DHODH inhibition may be broadly applicable against multiple viruses. IMU-838 was successfully tested in two phase 1 clinical trials in 2017 and is currently being tested in a phase 2 trial in patients with ulcerative colitis. In the third quarter of 2020, the company reported positive results from its phase 2 EMPhASIS trial of IMU-838 in relapsing-remitting multiple sclerosis, achieving both primary and key secondary endpoints with high statistical significance. In the first quarter of 2021, Immunic announced that IMU-838 showed evidence of clinical activity in its phase 2 CALVID-1 trial in hospitalized patients with moderate COVID-19. Also, in the first quarter of 2021, the company reported positive top-line data from an investigator-sponsored phase 2 proof-of-concept clinical trial of IMU-838 in primary sclerosing cholangitis which was conducted in collaboration with Mayo Clinic. To date, IMU-838 has been tested in more than 800 individuals and has shown an attractive pharmacokinetic, safety and tolerability profile. IMU-838 is not yet licensed or approved in any country.

About Immunic, Inc.

Immunic, Inc. (Nasdaq: IMUX) is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. The company is developing three small molecule products: its lead development program, IMU-838, a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH and exhibits a host-based antiviral effect, is currently being developed as a treatment option for multiple sclerosis, ulcerative colitis, Crohn’s disease, and primary sclerosing cholangitis. IMU-935, a selective inverse agonist of the transcription factor RORγt, is targeted for development in psoriasis and Guillain-Barré syndrome. IMU-856, which targets the restoration of the intestinal barrier function, is targeted for development in diseases involving bowel barrier dysfunction. For further information, please visit: www.imux.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses, prospects, plans and objectives of management are forward-looking statements. Examples of such statements relating to Immunic’s three development programs and the targeted diseases; the potential for IMU-838 to safely and effectively target diseases, including relapsing-remitting or progressive multiple sclerosis; preclinical and clinical data for IMU-838; the timing of current and future clinical trials; the availability, safety or efficacy of potential treatment options for patients with relapsing-remitting or progressive multiple sclerosis or other conditions, if any; the potential availability and frequency of administration of IMU-838 as a potential treatment for patients with relapsing-remitting or progressive multiple sclerosis or for patients with other conditions; preparations for a clinical phase 3 program for IMU-838 in relapsing-remitting multiple sclerosis; the nature, strategy and focus of the company and further updates with respect thereto; and the development and commercial potential of any product candidates of the company. Immunic may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Such statements are based on management’s current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, the COVID-19 pandemic, risks and uncertainties associated with the ability to project future cash utilization and reserves needed for contingent future liabilities and business operations, the availability of sufficient resources to meet business objectives and operational requirements, the fact that the results of earlier studies and trials may not be predictive of future clinical trial results, the protection and market exclusivity provided by Immunic’s intellectual property, risks related to the drug development and the regulatory approval process and the impact of competitive products and technological changes. A further list and descriptions of these risks, uncertainties and other factors can be found in the section captioned “Risk Factors,” in the company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020, filed with the SEC on February 26, 2021, and in the company’s subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov or ir.imux.com/sec-filings. Any forward-looking statement made in this release speaks only as of the date of this release. Immunic disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made. Immunic expressly disclaims all liability in respect to actions taken or not taken based on any or all the contents of this press release.

Contact Information

Immunic, Inc.

Jessica Breu

Head of Investor Relations and Communications
+49 89 2080 477 09
[email protected]

US IR Contact
Rx Communications Group
Paula Schwartz
+1-917-322-2216
[email protected]

US Media Contact
KOGS Communication
Edna Kaplan
+1 781 639 1910
[email protected]

 

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/immunic-inc-announces-fda-clearance-to-begin-imu-838-phase-3-ensure-studies-in-relapsing-remitting-multiple-sclerosis-and-phase-2-calliper-study-in-progressive-multiple-sclerosis-301324101.html

SOURCE Immunic, Inc.

Clorox Announces Aug. 3 Webcast of Fourth-Quarter and Fiscal Year 2021 Results

PR Newswire

OAKLAND, Calif., July 1, 2021 /PRNewswire/ — The Clorox Company (NYSE: CLX) announced today that on Tuesday, Aug. 3, it will host a live audio webcast of a discussion with the investment community about its fourth-quarter and fiscal year 2021 results.

The webcast is scheduled to begin at 10:30 a.m. PT (1:30 p.m. ET) and can be accessed at Clorox investor events. A replay of the webcast will be available on the company’s website.

The Clorox Company

The Clorox Company (NYSE: CLX) is a leading multinational manufacturer and marketer of consumer and professional products with about 8,800 employees worldwide and fiscal year 2020 sales of $6.7 billion. Clorox markets some of the most trusted and recognized consumer brand names, including its namesake bleach and cleaning products; Pine-Sol® cleaners; Liquid-Plumr® clog removers; Poett® home care products; Fresh Step® cat litter; Glad® bags and wraps; Kingsford® grilling products; Hidden Valley® dressings and sauces; Brita® water-filtration products; Burt’s Bees® natural personal care products; and RenewLife®, Rainbow Light®, Natural Vitality Calm™ and NeoCell® vitamins, minerals and supplements. The company also markets industry-leading products and technologies for professional customers, including those sold under the CloroxPro™ and Clorox Healthcare® brand names. More than 80% of the company’s sales are generated from brands that hold the No. 1 or No. 2 market share positions in their categories.

Clorox is a signatory of the United Nations Global Compact and the Ellen MacArthur Foundation’s New Plastics Economy Global Commitment. The company has been broadly recognized for its corporate responsibility efforts, listed on the Barron’s 2020 100 Most Sustainable Companies list, 2021 Bloomberg Gender-Equality Index and Human Rights Campaign’s 2021 Corporate Equality Index, among others. In support of its communities, The Clorox Company and its foundations contributed more than $25 million in combined cash grants, product donations and cause marketing in fiscal year 2020. For more information, visit TheCloroxCompany.com, including the Good Growth blog, and follow the company on Twitter at @CloroxCo.

CLX-F

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/clorox-announces-aug-3-webcast-of-fourth-quarter-and-fiscal-year-2021-results-301323789.html

SOURCE The Clorox Company